Shares of Fate Therapeutics Inc (NASDAQ:FATE) gapped down prior to trading on Friday . The stock had previously closed at $15.00, but opened at $15.74. Fate Therapeutics shares last traded at $16.49, with a volume of 13191 shares traded.
FATE has been the topic of a number of research reports. Jefferies Financial Group initiated coverage on shares of Fate Therapeutics in a report on Monday, November 5th. They issued a “buy” rating and a $17.00 target price on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price on shares of Fate Therapeutics in a report on Tuesday, September 25th. BidaskClub upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 25th. Finally, Zacks Investment Research upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 21st. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.25.
The company has a current ratio of 9.44, a quick ratio of 9.44 and a debt-to-equity ratio of 0.07. The firm has a market cap of $1.10 billion, a PE ratio of -16.29 and a beta of 2.05.
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.06). Fate Therapeutics had a negative net margin of 1,536.05% and a negative return on equity of 68.57%. The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.24 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. The firm’s revenue was up .0% compared to the same quarter last year. Equities research analysts forecast that Fate Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.
In other news, Director Redmile Group, Llc purchased 3,703,704 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were acquired at an average price of $13.50 per share, for a total transaction of $50,000,004.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.89% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Fate Therapeutics by 12.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,448,279 shares of the biopharmaceutical company’s stock valued at $39,882,000 after buying an additional 275,828 shares during the period. Neuberger Berman Group LLC increased its stake in Fate Therapeutics by 700.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 120,000 shares of the biopharmaceutical company’s stock valued at $1,955,000 after buying an additional 105,000 shares during the period. HRT Financial LLC acquired a new position in Fate Therapeutics in the 3rd quarter valued at approximately $583,000. MetLife Investment Advisors LLC increased its stake in Fate Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 35,818 shares of the biopharmaceutical company’s stock valued at $583,000 after buying an additional 12,740 shares during the period. Finally, Sofinnova Ventures Inc acquired a new position in Fate Therapeutics in the 3rd quarter valued at approximately $1,709,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Fate Therapeutics (FATE) Shares Gap Down to $15.74” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/12/07/fate-therapeutics-fate-shares-gap-down-to-15-74.html.
About Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors.
Recommended Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.